Gilead Sciences GILD Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.63B+0.8% | $7.56B+3.2% | $7.33B+42.5% | $5.14B-35.1% | $7.93B-20.7% | ||
| $15M-77.9% | $68M+258% | $19M-72.5% | $69M— | —— | ||
| $5.54B-6.0% | $5.9B-1.7% | $5.99B+6.6% | $5.62B+7.0% | $5.26B-1.2% | ||
| $2.42B-6.6% | $2.59B-0.3% | $2.6B+24.7% | $2.09B+3.4% | $2.02B+7.4% | ||
| $18.64B+1.6% | $18.34B+2.6% | $17.87B+21.4% | $14.72B-12.9% | $16.9B-11.8% | ||
| $5.64B+0.6% | $5.61B+1.9% | $5.5B+0.8% | $5.46B+0.7% | $5.42B+0.1% | ||
| $8.31B0.0% | $8.31B0.0% | $8.31B0.0% | $8.31B0.0% | $8.31B0.0% | ||
| $56.28B-4.7% | $59.02B+0.8% | $58.53B+5.0% | $55.72B-1.3% | $56.43B-4.3% | ||
| $645M-9.8% | $715M-11.5% | $808M+38.8% | $582M-21.0% | $737M-11.5% | ||
| $1.31B-53.2% | $2.81B0.0% | $2.81B0.0% | $2.81B0.0% | $2.81B+54.6% | ||
| $9.48B-19.8% | $11.81B-3.9% | $12.3B+9.9% | $11.19B-9.4% | $12.34B+2.8% | ||
| $20.86B-5.7% | $22.13B0.0% | $22.14B0.0% | $22.14B0.0% | $22.15B-11.0% | ||
| $14.13B+2.9% | $13.73B+7.1% | $12.83B+13.2% | $11.33B+3.6% | $10.93B-4.9% | ||
| $23.52B+3.6% | $22.7B+5.4% | $21.54B+9.5% | $19.67B+2.7% | $19.16B-0.9% | ||
| $56.28B-4.7% | $59.02B+0.8% | $58.53B+5.0% | $55.72B-1.3% | $56.43B-4.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gilead Sciences's total assets?
- Gilead Sciences (GILD) holds $56.3B in total assets, down 0.3% year over year.
- How much debt does Gilead Sciences have?
- Gilead Sciences carries $22.2B in total debt against $23.5B of shareholders' equity, a debt-to-equity ratio of 0.94.
- How much cash does Gilead Sciences have?
- Gilead Sciences holds $7.6B in cash and equivalents.
- Can Gilead Sciences cover its short-term obligations?
- Its current ratio is 1.97 — current assets exceed current liabilities.
- Where does Gilead Sciences's balance sheet data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
